Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 29'th May 2026
VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, cl
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
01:24pm, Monday, 18'th May 2026
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:40pm, Thursday, 14'th May 2026
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Q1 Earnings Call Highlights
04:07am, Saturday, 09'th May 2026
Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
03:41am, Friday, 08'th May 2026
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Xenon Reports Q1 2026 Financial Results and Provides Business Update
04:01pm, Thursday, 07'th May 2026
VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, cl
Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026
08:44am, Thursday, 07'th May 2026
Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 01'st May 2026
VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, cl
Xenon to Report Q1 2026 Financial Results on May 7, 2026
04:01pm, Thursday, 30'th Apr 2026
VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium
04:51pm, Wednesday, 22'nd Apr 2026
Xenon Pharmaceuticals Inc.'s bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. Azetukalner's differentiated Kv7 mechanism, once-daily do
VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,
Xenon to Present at Upcoming Investor Conferences
08:30am, Wednesday, 15'th Apr 2026
VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
08:30am, Tuesday, 07'th Apr 2026
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-te
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
01:09am, Thursday, 02'nd Apr 2026
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of 2,3
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
07:03pm, Friday, 27'th Mar 2026
The chief medical officer of Xenon Pharmaceuticals directly sold 1,410 common shares for a transaction value of $78,000 on March 13, 2026. This sale represented 16.63% of his direct common stock holdi
